Vanda’s First Quarter 2026: NEREUS Launch Lifts Revenue Outlook as the Portfolio Recalibrates

Financial highlights at a glance

Vanda Pharmaceuticals Inc. (VNDA) reported a first quarter ended March 31, 2026 with net product sales totaling $51.7 million, up 3% from $50.0 million in Q1 2025. The sales mix underscores the company’s reliance on a few key products as it shifts toward newer growth engines.

• Fanapt net product sales were $29.6 million, up 26% year over year, supported by higher prescriptions and an improving new-to-brand trajectory.
• HETLIOZ net product sales were $15.9 million, down 24% year over year, illustrating continued volume headwinds as the portfolio cycles.
• PONVORY net product sales were $6.2 million, up 10% year over year, contributing modestly to the top line while the company pivots toward near-term catalysts.
• Loss before income taxes totaled $48.4 million, versus $37.4 million in Q1 2025, reflecting ongoing investments in launches and pipeline progression rather than operating leverage in the near term.

Strategic moves and pipeline updates

The quarter was marked by a mix of commercialization milestones and pipeline milestones that could shape revenue trajectories over the next 12–24 months.

• NEREUS—A direct‑to‑consumer platform (nereus.us) launched alongside its motion sickness indication, described as the first new prescription medicine in more than 40 years for vomiting prevention. The launch is paired with a consumer-centric distribution model intended to accelerate access and online ordering with rapid home delivery.
• Revenue contribution from NEREUS—The company guided full-year 2026 revenue to a range of $240–$290 million, including roughly $10–$30 million from the newly launched NEREUS. The magnitude of that contribution will be watched closely as the platform matures.
• BYSANTI (milsaperidone) received FDA approval for bipolar I disorder and schizophrenia on February 20, 2026, expanding the company’s portfolio and potential revenue stream in mood disorders.
• Imsidolimab BLA for Generalized Pustular Psoriasis was accepted for FDA review, with a PDUFA target action date of December 12, 2026, providing a potential near-term clinical and regulatory event risk for investors.

Outlook and implications for VNDA and sector peers

The Q1 numbers are a reminder that growth for Vanda hinges on a portfolio blend: robust Fanapt performance, a softer HETLIOZ, and a nascent but potentially transformative NEREUS launch. For investors, the question is whether the revenue forecast for 2026 can be translated into a meaningful path to positive earnings per share (EPS) or whether the company will continue to run EBITDA losses as it funds launches and pipeline work.

From an earnings‑oriented lens, there is no explicit EPS figure in the release, which means that any assessment of an earnings surprise versus EPS consensus will require consensus estimates from sell-side models. If the market had baked in a tighter loss or a modest margin improvement, the Q1 results could have sparked an EPS beat or miss discussion; in the absence of a reported EPS, the narrative centers on top-line momentum and the quality of the pipeline.

Strategically, the NEREUS launch and its online channel could pressure peers to emphasize consumer access and direct-to-patient pathways, especially in channels where patients can initiate purchases online. The BYSANTI approval adds optionality for mid-term growth, while the Imsidolimab PDUFA date remains a focal point for investors tracking pipeline value vs. near-term execution.

In terms of sector dynamics, VNDA’s push on new products and consumer access aligns with a broader trend of specialty pharma diversifying revenue beyond established flagships. The challenge remains the burn associated with launches and R&D, which will test the company’s ability to translate pipeline progress into higher EPS over time. If the 2026 revenue forecast proves durable, the stock could reframe from a pure growth story to a growth-plus-recovery story—one where an earnings surprise would be less about a one-quarter beat and more about a sustained trajectory toward profitability.

Executive commentary

“Vanda delivered strong commercial execution in the first quarter, highlighted by Fanapt growth, the US launch of NEREUS with its pioneering direct-to-consumer platform, and the regulatory progress on BYSANTI,” said Mihael H. Polymeropoulos, M.D., Vanda’s President, CEO and Chairman of the Board. “We believe these achievements, combined with meaningful pipeline progress and our raised 2026 revenue guidance, position the company for continued growth and value creation.”

Takeaways for investors

Key points to watch going forward include: whether Fanapt sustains its 2026 momentum, how the NEREUS platform scales and contributes to revenue, and how Imsidolimab and BYSANTI progress through regulatory and commercialization milestones. The EPS trajectory remains uncertain in the near term, so market participants will be keen on the EPS consensus and any signs of a positive earnings surprise as the company beds down its 2026 plan. In the near term, VNDA’s stock will likely move on pipeline milestones and the pace of NEREUS adoption as much as on quarterly revenue performance.

Bottom line: VNDA is trading on a mix of tangible product progress and the promise of a more expansive pipeline. If the company can convert 2026 revenue guidance into sustainable earnings power, the rest of the sector might start treating Vanda like a blueprint for how to balance a legacy portfolio with high‑beta new ventures.